Exactly runner, its the consistency of the patches. They said that they didnt want to leave anything to chance in the phase 2/3 trials and although they could produce in-house the lower level of consistency could jeapordise the trials.
it's the right move. At the serious phase of development you dont want to be cutting corners. And the added advantage is that the patches can be used for commercial rollout almost immediately should pahse 2/3 trials prove successful.
Exactly runner, its the consistency of the patches. They said...
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
